Skip to main content
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.980
+0.180 (4.74%)
At close: Dec 5, 2025, 4:00 PM EST
3.900
-0.080 (-2.01%)
After-hours: Dec 5, 2025, 7:57 PM EST

SAB Biotherapeutics Revenue

SAB Biotherapeutics had revenue of $114.70K in the twelve months ending September 30, 2025, down -92.42% year-over-year. In the year 2024, SAB Biotherapeutics had annual revenue of $1.32M, down -40.94%.

Revenue (ttm)
$114.70K
Revenue Growth
-92.42%
P/S Ratio
1,651.95
Revenue / Employee
$1,821
Employees
63
Market Cap
189.48M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20241.32M-916.58K-40.94%
Dec 31, 20232.24M-21.67M-90.63%
Dec 31, 202223.90M-36.97M-60.73%
Dec 31, 202160.88M5.64M10.21%
Dec 31, 202055.24M51.80M1,504.91%
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 435.16B
Johnson & Johnson 92.15B
Merck & Co. 64.24B
AbbVie 59.64B
Eli Lilly and Company 59.42B
AstraZeneca 58.13B
Novartis AG 56.37B
Novo Nordisk 49.58B
Revenue Rankings

SABS News

More News